세계의 In Vivo CRO 시장 - 규모, 점유율, 동향 분석 보고서 : 모델 유형별, 모달리티별, 적응증별, GLP 유형별, 지역별, 부문 예측(2025-2030년)

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,521,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,953,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,818,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

In Vivo CRO 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 In Vivo CRO 시장 규모는 2030년까지 79억 6,000만 달러에 이르며, 2025년부터 2030년까지의 CAGR은 8.13%로 확대될 것으로 추정됩니다.

신흥국의 의약품 시장 성장, 수많은 In Vivo 세포 치료에 대한 왕성한 수요, 재료 과학의 급속한 진보, 약물과 장치의 조합의 복잡성 등이 이 지역의 서비스 수요로 이어지고 있습니다., In Vivo 전임상 및 임상 연구 증가, 규제 당국의 승인, 시장 진출기업에 의한 서비스의 확대, 다양한 질병의 부담이 시장 수익에 기여하고 있습니다.에서 아웃소싱 증가는 In Vivo CRO 시장의 성장을 지원하는 주요 요인 중 하나입니다.

마찬가지로 신흥국에 대한 의약품의 해외가 증가하고 있는 것도 이 시장에 막대한 수요를 창출하고 있습니다. 선진국에서의 예산의 조사, 가격압력, 상환제도의 변경은 인도나 중국 등 신흥 국가에서의 의약품 후원자에 의한 비용억제책의 채용을 증가시킬 것으로 예상되는 주요 요인의 일부입니다. 신흥 국가에서는 전임상 In Vivo 서비스 등의 개발 서비스를 계약 서비스 제공업체에게 아웃소싱함으로써 품질보증·약사 서비스에 대한 수요가 높아지고 In Vivo 아웃소싱 서비스 수요 증가에 기여할 것으로 예상됩니다. FDA 승인을 위한 엄격한 프로세스와 EU 지역의 규제 변경은 유럽에서 승인 프로세스를 복잡하게 만들 것으로 예상됩니다. 이들은 제약 회사의 신흥 국가로 해외에 기여하는 주요 요인 중 하나입니다.

COVID-19 팬데믹은 당초 임상시험 업계에 악영향을 주었지만, In Vivo CRO 시장도 마찬가지였습니다. COVID-19에 대응하여 바이오의약품업계가 백신과 치료법의 개발에 중점을 옮긴 결과, 다른 질환의 임상시험을 혼란시킬 가능성이라는 예기치 않은 결과를 초래했습니다. 세포 및 유전자 치료 업계에서 사업을 전개하는 기업이 직면하는 중요한 문제 중 하나는 필요한 임상시험 실시 시설에서 환자에게 치료제를 적시에 제공할 수 없다는 것입니다. 게다가, 세포 기반 치료제의 투여는 유행 후에 몇 가지 과제를 야기합니다. 병원은 SARS-CoV-2의 트랜스미션, 특히 약한 입장의 사람에 대한 감염을 우려하고, 세포 치료 서비스의 제공을 망설이고 있습니다. 환자는 잠금 및 여행 금지를 위해 세포 치료 센터를 방문 할 수 없습니다.

또한 주요 진출기업은 세계 실적 및 서비스/제품 포트폴리오를 확대하기 위해 M&A, 파트너십, 협정, 제휴, 서비스 개시 등의 전략을 추진하고 있습니다. PsychoGenics, Inc.는 표현형 창약을 강화하기 위한 약리뇌파 플랫폼인 eCube의 발매를 발표했습니다. 전인간형 나노바디 의약품을 개발하는 「나노 100 프로젝트」를 발표했습니다. in vitro 및 In Vivo 항체 스크리닝 플랫폼을 결합한 이 통합 기술을 활용하여 바이오시토겐은 완전 인간형 나노바디 의약품의 광범위한 개발을 촉진하는 태세를 갖추고 있습니다.

In Vivo CRO 시장 보고서 하이라이트

• 설치류는 유전적으로 인간과 유사하기 때문에 일정한 수요가 있습니다. 가장 보급되고 있는 동물종입니다.
• 저분자 부문은 In Vivo CRO 시장을 독점하고 있습니다. 이 부문의 성장을 뒷받침하고 있습니다.
• 암 분야는 In Vivo CRO 세계 시장을 독점했으며, 2024년에는 29.02%의 매출 점유율을 차지했습니다. 암 면역요법을 위한 전임상시험 등을 들 수 있습니다. T세포요법의 약 97%는 암을 적응증으로서 개발되고 있습니다.
• 중추신경계 질환 분야는 뇌질환을 표적으로 한 다양한 모델 기반의 임상시험약의 효능에 의해 가장 빠른 성장이 예상되고 있습니다.
• GLP 독성학 부문은 특정 가이드라인에 따라 실시되는 표준화 시험 증가로 2024년에 최대의 수익 점유율을 획득하여 시장을 독점했습니다.
• 북미는 2024년 In Vivo CRO 시장에서 50.0%의 최대 수익 점유율을 차지했습니다. 기타 성장 요인은 연구 개발 활동, 전임상시험, 시장 기업의 혁신 증가입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 In Vivo CRO 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• In Vivo CRO 시장 분석 도구
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 In Vivo CRO 시장 : 모달리티 추정·동향 분석

• In Vivo CRO 시장, 모달리티별: 부문 대시보드
• In Vivo CRO 시장, 모달리티별: 변동 분석
• 모달리티별, 2018-2030년
• 소분자
  • 저분자 시장, 2018-2030년
• 거대분자
  • 거대분자 시장, 2018-2030년
  • 세포 및 유전자 치료
  • RNA 요법
  • 기타

제5장 In Vivo CRO 시장 : 모델 유형 추정·동향 분석

• In Vivo CRO 시장, 모델 유형별: 부문 대시보드
• In Vivo CRO 시장, 모델 유형별: 변동 분석
• 모델 유형별, 2018-2030년
• 설치류 베이스
  • 설치류 베이스 시장, 2018-2030년
  • 쥐 모델
  • 마우스 모델
  • 기타
• 비설치류 베이스
  • 비 설치류 베이스 시장, 2018-2030년

제6장 In Vivo CRO 시장 : 적응증 추정·동향 분석

• In Vivo CRO 시장, 적응증별: 부문 대시보드
• In Vivo CRO 시장, 적응증별: 변동 분석
• 적응증별, 2018-2030년
• 자가면역질환/염증성질환
  • 자가면역질환/염증질환시장, 2018-2030년
  • 류마티스 관절
  • 다발성 경화증
  • 골관절염
  • 과민성 장 증후군
  • 기타
• 통증 관리
  • 통증 관리 시장, 2018-2030년
  • 만성 통증
  • 급성 통증
• 종양학
  • 종양학 시장, 2018-2030년
  • 혈액암
  • 고형 종양
  • 기타
• 중추신경계의 증상
  • CNS 질환 시장, 2018-2030년
  • 간질
  • 파킨슨병
  • 헌팅턴병
  • 뇌졸중
  • 근이영양증
  • 알츠하이머병
  • 외상성 뇌 손상
  • 근위축성 측삭 경화증(ALS)
  • 척수성 근위축증
  • 근육의 재생
  • 기타 신경 발달 장애
• 당뇨병
  • 당뇨병 시장, 2018-2030년
• 비만
  • 비만 시장, 2018-2030년
• 기타
  • 기타 시장, 2018-2030년

제7장 In Vivo CRO 시장 : GLP 유형 추정·동향 분석

• In Vivo CRO 시장, GLP 유형별: 부문 대시보드
• In Vivo CRO 시장, GLP 유형별: 변동 분석
• GLP 유형별, 2018-2030년
• 비 GLP
  • 비 GLP 시장, 2018-2030년
• GLP 독성학
  • GLP 독성학 베이스 시장, 2018-2030년

제8장 In Vivo CRO 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년·2030년
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 시장 진출기업의 분류
• 기업의 시장 점유율 분석, 2023/24년
• 기업 프로파일
  • IQVIA Inc
  • Crown Bioscience
  • Taconic Biosciences, Inc.
  • PsychoGenics Inc.
  • Evotec
  • Janvier Labs
  • Biocytogen
  • GemPharmatech
  • Charles River Laboratories
  • Icon Plc
  • Labcorp Drug Development
  • Parexel International Corporation
  • SMO Clinical Research(I) Pvt Ltd

제10장 주요 권고

JHS

영문 목차

영문목차

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is estimated to reach USD 7.96 billion by 2030, expanding at a CAGR of 8.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

• The rodent-based segment held the largest revenue share of 81.95% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
• The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
• The oncology segment dominated the global in vivo CRO market and accounted for a revenue share of 29.02% in 2024, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
• The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
• The GLP toxicology segment dominated the market with the largest revenue share in 2024 owing to the increasing number of standardized studies conducted according to specific guidelines
• North America held the largest revenue share of 50.0% in in-vivo CRO market in 2024. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Modality
  • 1.2.2. Model Type
  • 1.2.3. Indication
  • 1.2.4. GLP Type
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Changing regulatory landscape
    • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
    • 3.2.1.3. Rising demand for advanced products
    • 3.2.1.4. Implementation of international standards by contract manufacturers
    • 3.2.1.5. Rising price competition and requirement to reduce cost
    • 3.2.1.6. Increasing complexity concerning product design and engineering
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Countries
    • 3.2.2.3. Regulatory And Legal Compliance
    • 3.2.2.4. Contractual Obligation
• 3.3. In Vivo CRO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. In Vivo CRO Market: Modality Estimates & Trend Analysis

• 4.1. In Vivo CRO Market, By Modality: Segment Dashboard
• 4.2. In Vivo CRO Market, By Modality: Movement Analysis
• 4.3. In Vivo CRO Market Estimates & Forecasts, By Modality, 2018 - 2030
• 4.4. Small Molecule
  • 4.4.1. Small Molecule Market, 2018 to 2030 (USD Million)
• 4.5. Large Molecule
  • 4.5.1. Large Molecule Market, 2018 to 2030 (USD Million)
  • 4.5.2. Cell & Gene Therapy
    • 4.5.2.1. Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.2.2. CAR T-cell therapies
      • 4.5.2.2.1. CAR T-Cell Therapies Market, 2018 to 2030 (USD Million)
    • 4.5.2.3. CAR-NK cell therapy
      • 4.5.2.3.1. CAR-NK Cell Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.2.4. TCR-T cell therapy
      • 4.5.2.4.1. TCR-T Cell Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.2.5. Other Cell & Gene Therapy
      • 4.5.2.5.1. Other Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
  • 4.5.3. RNA Therapy
    • 4.5.3.1. RNA Therapy Market, 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market, 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Model Type Estimates & Trend Analysis

• 5.1. In Vivo CRO Market, By Model Type: Segment Dashboard
• 5.2. In Vivo CRO Market, By Model Type: Movement Analysis
• 5.3. In Vivo CRO Market Estimates & Forecasts, By Model Type, 2018 - 2030
• 5.4. Rodent based
  • 5.4.1. Rodent based Market, 2018 to 2030 (USD Million)
  • 5.4.2. Rat Models
    • 5.4.2.1. Rat Models Market, 2018 to 2030 (USD Million)
  • 5.4.3. Mice Models
    • 5.4.3.1. Mice Models Market, 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market, 2018 to 2030 (USD Million)
• 5.5. Non-Rodent based
  • 5.5.1. Non-Rodent based Market, 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

• 6.1. In Vivo CRO Market, By Indication: Segment Dashboard
• 6.2. In Vivo CRO Market, By Indication: Movement Analysis
• 6.3. In Vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
• 6.4. Autoimmune/inflammation conditions
  • 6.4.1. Autoimmune/inflammation conditions Market, 2018 to 2030 (USD Million)
  • 6.4.2. Rheumatoid Arthritis
    • 6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
  • 6.4.3. Multiple Sclerosis
    • 6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
  • 6.4.4. Osteoarthritis
    • 6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
  • 6.4.5. Irritable Bowel Syndrome
    • 6.4.5.1. Irritable Bowel Syndrome Market, 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Others Market, 2018 to 2030 (USD Million)
• 6.5. Pain management
  • 6.5.1. Pain management Market, 2018 to 2030 (USD Million)
  • 6.5.2. Chronic pain
    • 6.5.2.1. Chronic pain Market, 2018 to 2030 (USD Million)
  • 6.5.3. Acute pain
    • 6.5.3.1. Acute pain Market, 2018 to 2030 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology Market, 2018 to 2030 (USD Million)
  • 6.6.2. Blood cancer
    • 6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
  • 6.6.3. Solid tumor
    • 6.6.3.1. Solid Tumor Market, 2018 to 2030 (USD Million)
    • 6.6.3.2. Syngeneic model
      • 6.6.3.2.1. Syngeneic Model Market, 2018 to 2030 (USD Million)
    • 6.6.3.3. Patient derived xenograft
      • 6.6.3.3.1. Patient Derived Xenograft Market, 2018 to 2030 (USD Million)
    • 6.6.3.4. Xenograft
      • 6.6.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)
  • 6.6.4. Others
    • 6.6.4.1. Others Market, 2018 to 2030 (USD Million)
• 6.7. CNS Conditions
  • 6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
  • 6.7.2. Epilepsy
    • 6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
  • 6.7.3. Parkinson's disease
    • 6.7.3.1. Parkinson's Disease Market, 2018 to 2030 (USD Million)
  • 6.7.4. Huntington's disease
    • 6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
  • 6.7.5. Stroke
    • 6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
  • 6.7.6. Muscular Dystrophy
    • 6.7.6.1. Muscular Dystrophy Market, 2018 to 2030 (USD Million)
  • 6.7.7. Alzheimer's Disease
    • 6.7.7.1. Alzheimer's Disease Market, 2018 to 2030 (USD Million)
  • 6.7.8. Traumatic brain injury
    • 6.7.8.1. Traumatic Brain Injury Market, 2018 to 2030 (USD Million)
  • 6.7.9. Amyotrophic lateral sclerosis (ALS)
    • 6.7.9.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
  • 6.7.10. Spinal Muscular Atrophy
    • 6.7.10.1. Spinal Muscular Atrophy Market, 2018 to 2030 (USD Million)
  • 6.7.11. Muscle regeneration
    • 6.7.11.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
  • 6.7.12. Other Neurodevelopment Disorders
    • 6.7.12.1. Other Neurodevelopment Disorders Market, 2018 to 2030 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
• 6.9. Obesity
  • 6.9.1. Obesity Market, 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market, 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

• 7.1. In Vivo CRO Market, By GLP Type: Segment Dashboard
• 7.2. In Vivo CRO Market, By GLP Type: Movement Analysis
• 7.3. In Vivo CRO Market Estimates & Forecasts, By GLP Type, 2018 - 2030
• 7.4. Non GLP
  • 7.4.1. Non GLP Market, 2018 to 2030 (USD Million)
• 7.5. GLP Toxicology
  • 7.5.1. GLP Toxicology based Market, 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Share Analysis, 2023/24
• 9.3. Company Profiles
  • 9.3.1. IQVIA Inc
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Crown Bioscience
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Taconic Biosciences, Inc.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. PsychoGenics Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Evotec
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Janvier Labs
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Biocytogen
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. GemPharmatech
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Charles River Laboratories
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Icon Plc
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Labcorp Drug Development
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Parexel International Corporation
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. SMO Clinical Research (I) Pvt Ltd
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives

Chapter 10 Key Recommendations

관련자료